Synplogen and Ginkgo Bioworks sign MoU for DNA manufacture
Pharmaceutical Technology
DECEMBER 7, 2023
Synplogen and Ginkgo Bioworks have signed an MOU to expedite DNA manufacturing and gene therapy platform services in Japan.
New facility boosts UK’s cell and gene therapy manufacturing capacity
Pharmaceutical Technology
MARCH 10, 2023
On 10 March, the National Health Service Blood and Transplant (NHSBT) opened a new Clinical Biotechnology Centre (CBC) with the aim of improving the UK’s ability to develop and manufacture cell and gene therapies. This is important due to the UK’s currently limited short-scale manufacturing capacity.
Gene Therapy 
264
264 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioNTech completes first in-house plasmid DNA manufacturing facility
BioPharma Reporter
FEBRUARY 2, 2023
mRNA pioneer BioNTech has completed construction of its first proprietary plasmid DNA manufacturing facility in Marburg, Germany.
DNA 105
105 
4basebio receives MHRA licence for synthetic DNA manufacture
Pharma Times
APRIL 2, 2025
GMP certification enables 4basebio to supply DNA for clinical trials
DNA 92
92 
Moderna makes its first-ever acquisition, buying Japanese DNA manufacturer OriCiro for $85M
Fierce Pharma
JANUARY 4, 2023
Moderna makes its first-ever acquisition, buying Japanese DNA manufacturer OriCiro for $85M. Wed, 01/04/2023 - 06:37.
DNA 104
104 
Logistics in Focus: Orchestrating the Challenges of Cell Therapy
Worldwide Clinical Trials
NOVEMBER 12, 2024
For example, once considered incurable and terminal, patients with sickle cell disease may reach new summits in their lives with gene editing technologies such as CRISPR to repair affected DNA and, in some cases, functionally cure the condition. Operationalizing these trials requires proactive and flawless management at every stage.
Gene Therapy 182
182 
DNA plasmid manufacturer taking orders for mid-2022 production slots at new site
BioPharma Reporter
OCTOBER 5, 2021
VGXI, Inc, a provider of plasmid DNA manufacturing and development services, says multiple construction milestones have been reached for its new headquarters and manufacturing facility in Texas.
DNA 90
90 
GenScript ProBio and RVAC partner for Covid-19 vaccine pDNA
Pharmaceutical Technology
FEBRUARY 23, 2023
GenScript ProBio has announced a strategic collaboration with RVAC Medicines to manufacture GMP-grade plasmid DNA (pDNA) for the latter’s RVM-V001, an mRNA Covid-19 vaccine candidate. Under the agreement, GenScript ProBio will offer GMP plasmid manufacturing service for the RVM-V001 programme.
Vaccine 289
289 
Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site
Pharma Mirror
FEBRUARY 23, 2021
Catalent is also announcing the launch of pDNA development and manufacturing services at its Rockville, Maryland facility. The post Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site appeared first on Pharma Mirror Magazine. SOMERSET, N.J. SOMERSET, N.J.
Genetics 130
130 
Thermo Fisher Opens Plasmid DNA Manufacturing Facility in California
BioSpace
JULY 14, 2021
Thermo Fisher Scientific continues to open new facilities that enable it to meet increasing manufacturing demands.
Manufacturing 100
100 
Forge adds plasmid DNA manufacturing to integrate gene therapy production service
BioPharma Reporter
OCTOBER 20, 2022
Forge Biologics has added plasmid DNA manufacturing to its roster of services, enabling it to vertically integrate its production process.
DNA 73
73 
Touchlight and Versameb in enzymatic DNA development and manufacturing deal
BioPharma Reporter
MARCH 3, 2022
UK headquartered Touchlight has agreed a development and manufacturing pipeline agreement with Swiss company, Versameb.
COVID prompts another milestone, as India clears first DNA vaccine
pharmaphorum
AUGUST 23, 2021
The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.
DNA 98
98 
DNA production specialist Touchlight raises £42m
Pharma Times
MARCH 11, 2021
Proceeds will be used to ‘more than triple’ UK biotech's manufacturing capabilities
DNA 123
123 
Thermo Fisher plots layoffs at California plasmid manufacturing site as demand swings
Fierce Pharma
APRIL 3, 2024
Demand fluctuations have spurred Thermo Fisher Scientific to downsize at the plasmid DNA manufacturing facility the company opened a little less than three years ago, putting jobs on the chopping b | Demand fluctuations have spurred Thermo Fisher Scientific to downsize at the plasmid DNA manufacturing facility the company opened a little less than (..)
Touchlight and Odimma enter cancer therapy clinical material supply agreement
Pharmaceutical Technology
DECEMBER 8, 2022
Developing neoantigen products needed for the therapy has faced difficulties including lead time to get GMP DNA and complicated supply chains. With a five-day manufacturing process, the enzymatic production approach of Touchlight will back Odimma in developing its programme. . It is manufactured using an enzymatic production process.
DNA 147
147 
Sartorius upscales gene therapy prowess with $2.6bn Polyplus acquisition
Pharmaceutical Technology
APRIL 3, 2023
The deal will see Polyplus join the German life science group’s portfolio allowing the latter to leverage expertise in transfection reagents and plasmid DNA for gene therapy. The company has been recently focusing on plasmid design and manufacturing through acquisitions of Xpress Biologics this year and e-Zyvec in 2022.
Gene Therapy 246
246 
CDMO Bionova branches into plasmid DNA to serve cell and gene therapy developers
Fierce Pharma
JUNE 3, 2024
As Japanese chemical giant Asahi Kasei continues its foray into the biopharma contract manufacturing space, the company’s biologics CDMO is expanding its offerings to include starting materials for | Asahi’s U.S. As part of the pDNA pivot, Bionova is setting up a new facility in The Woodlands, Texas.
DNA 80
80 
Touchlight joins forces with University of Liverpool for NSCLC vaccine
Pharmaceutical Technology
APRIL 4, 2024
The vaccines will be developed using Touchlight’s doggybone DNA technology, which speeds up the manufacturing process.
Vaccine 130
130 
Touchlight set to break ground on world’s highest-capacity DNA manufacturing facility
BioPharma Reporter
OCTOBER 18, 2021
Touchlight, a synthetic DNA producer, says it has received the first phase of planning approval for breaking ground on its new research and manufacturing facility in Hampton, UK.
DNA 59
59 
Lab to jab in 100 days: manufacturing flexibility for future rapid responses
Pharmaceutical Technology
NOVEMBER 22, 2022
This approach to vaccination offers many advantages to developers, including quick development, high potency, a favorable safety profile, and the potential for cost-effective manufacturing. An imbalance between supply and demand of plasmid DNA — a key raw material in mRNA production — has also become a bottleneck. .
Manufacturing 130
130 
Top 30 New Medical Devices of 2024
XTalks
JANUARY 21, 2025
TriClip G4 System Manufacturer/developer : Abbott Medical Date of FDA approval : April 1, 2024 Approved for : Tricuspid regurgitation (TR). Abbott Spinal Cord Stimulation (SCS) Systems Manufacturer/developer : Abbott Medical Date of FDA approval : May 30, 2024 Approved for : Chronic, hard-to-manage pain in the torso, arms and legs.
FDA Approval 105
105 
Thermo Fisher to build new California plasmid DNA production site, expands pharma services and sterile drug manufacturer footprint in EU and US
BioPharma Reporter
DECEMBER 16, 2020
Thermo Fisher Scientific today announced the construction of a new cGMP plasmid DNA manufacturing facility at its site in Carlsbad, California.
DNA 57
57 
Biovectra to Build First mRNA Vaccine and Drug Manufacturing Plant in Canada
XTalks
NOVEMBER 23, 2021
Canadian pharma and biotech contract development and manufacturing organization (CDMO) Biovectra has announced plans for building one of the first state-of-the-art mRNA vaccine and biomanufacturing facilities in Canada. This left the country without production capabilities for large-scale manufacturing of COVID-19 vaccines.
FDA accepts GMP plasmid DMF: Andelyn now ‘on track’ to speed up gene therapy development
BioPharma Reporter
JANUARY 17, 2022
Andelyn Biosciences says the FDA's acceptance of its GMP plasmid DNA drug master file (DMF) enables the CDMO to vertically integrate its clientsâ manufacturing process, condensing timelines for developers to begin manufacturing to just three months.
Gene Therapy 103
103 
Cytovance Biologics offers Nature Technology Corporation’s proprietary HyperGRO™ manufacturing platform for plasmid DNA CGMP manufacturing
BioTech 365
NOVEMBER 30, 2020
Cytovance Biologics offers Nature Technology Corporation’s proprietary HyperGRO™ manufacturing platform for plasmid DNA CGMP manufacturing Cytovance Biologics offers Nature Technology Corporation’s proprietary HyperGRO™ manufacturing platform for plasmid DNA CGMP manufacturing OKLAHOMA CITY, Nov.
DNA 40
40 
Lonza gains access to Touchlight’s enzymatic DNA technology
BioPharma Reporter
SEPTEMBER 8, 2022
A collaboration between Touchlight and Lonza expands the Swiss CDMOâs end-to-end offering for mRNA manufacturing with an additional, differentiated source of DNA raw material, the UK biotechâs doggybone DNA (dbDNA).
DNA 52
52 
Applied DNA CEO Discusses Relevance of DNA-based Cotton Traceability as Enabler of Ethical and Responsible Textile Manufacturing on BBC Business Daily
BioTech 365
APRIL 8, 2021
Applied DNA CEO Discusses Relevance of DNA-based Cotton Traceability as Enabler of Ethical and Responsible Textile Manufacturing on BBC Business Daily Applied DNA CEO Discusses Relevance of DNA-based Cotton Traceability as Enabler of Ethical and Responsible Textile Manufacturing on BBC … Continue reading →
DNA 40
40 
Celsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion’s DNA-based Vaccine
BioTech 365
SEPTEMBER 17, 2021
Celsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion’s DNA-based Vaccine Celsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion’s DNA-based Vaccine Expands GEN-1 Program Collaboration to Add Clinical and Commercial Batches of Investigational Vaccine LAWRENCEVILLE, N.J.
DNA 40
40 
DNA DATA STORAGE: RESEARCH LANDSCAPE AND FUTURE PROSPECTS
Roots Analysis
DECEMBER 12, 2021
DNA data storage involves encoding and decoding binary data to and from synthesized strands of DNA. DNA data storage is an innovative technology that works by encoding large digital data sequences of binary form (0s and 1s) into DNA sequences (Adenine (A), Guanine (G), Cytosine (C) and Thymine (T)). DNA Storage.
DNA 52
52 
Advanced Biomed IPO Raises $6.56M Towards Liquid Biopsy Testing
XTalks
MARCH 17, 2025
Recent pre-mass production trials tests conducted to ensure that the devices meet performance and manufacturing quality standards before full-scale production demonstrated that the A+Pre chip recovered 94% of tumor cells, while the AC-1000 achieved a 79.5% recovery rate, surpassing their performance targets.
Production 71
71 
Zydus gets FDA approval for antibiotic drug azithromycin
Pharmaceutical Technology
APRIL 11, 2023
The approval enables the company to manufacture and market azithromycin to treat infections such as bronchitis, pneumonia and sexually transmitted diseases (STDs). Zydus will manufacture the drug at its formulation facility in Moraiya, Ahmedabad, in the Indian state of Gujarat.
FDA Approval 130
130 
#news #biotech Touchlight extends funding round to boost DNA vector manufacture
BioTech 365
SEPTEMBER 15, 2021
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Touchlight extends funding round to boost DNA vector manufacture. from European Biotechnology – first and foremost in European biotech [link].
DNA 40
40 Enzychem to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea
BioTech 365
NOVEMBER 26, 2021
Enzychem to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea Enzychem to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea Technology Transfer spanning the complete production process Enzychem shall produce 80 million … Continue reading →
DNA 40
40 
Viral Vectors and Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report 2021 – 2028 – ResearchAndMarkets.com
BioTech 365
JUNE 15, 2021
Viral Vectors and Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report 2021 – 2028 – ResearchAndMarkets.com Viral Vectors and Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report 2021 – 2028 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Viral Vectors … (..)
DNA 40
40 
DNA Process Development & Manufacturing Summit
pharmaphorum
OCTOBER 19, 2023
Innovative biopharma including BioNTech, Genentech, AskBio, Pfizer, Roche, Sanofi and more will unite in Boston
DNA 52
52 
The future of the gene therapy market: driving innovations in biotherapeutics
Pharmaceutical Technology
OCTOBER 26, 2022
Gene therapy uses DNA to manipulate cells and correct defective genes, whereas cell therapy is the infusion or transplantation of cells into a patient. New doors were opened in the 2000s with the development of genome editing, such as CRISPR-Cas9, which introduces molecular tools to change existing DNA.
Gene Therapy 130
130 
AGC Biologics invests in Germany to address booming mRNA industry
BioPharma Reporter
SEPTEMBER 16, 2021
AGC Biologics is expanding its Heidelberg facility to create new capacity for messenger RNA (mRNA) projects, and to boost its plasmid-DNA (pDNA) manufacturing capabilities.
RNA 88
88 
Global Viral Vector and Plasmid DNA Manufacturing Market (2020 to 2030) – Growth, Trends, and Forecasts – ResearchAndMarkets.com
BioTech 365
OCTOBER 28, 2020
DUBLIN–(BUSINESS WIRE)–The “Viral Vector and Plasmid DNA Manufacturing Market – Growth, Trends, and Forecasts (2020 – 2025)” report has been added to ResearchAndMarkets.com’s offering.
DNA 40
40 
Generating Over a Billion Cells with CRISPR for Next Generation Cell Therapies
XTalks
AUGUST 29, 2022
Viral vectors have traditionally been used in gene editing where the shells of viruses carry the template DNA into cells, but this method has its disadvantages. It is difficult to control where the viral vectors insert genes in the genome, and it is difficult to manufacture large quantities of clinical-grade viral vectors.
Gene Editing 98
98 
Touchlight appoints Karen Fallen as CEO of Touchlight DNA Services
Drug Discovery Today
OCTOBER 19, 2020
Former Lonza President of Biologics Manufacturing joins to continue rapid expansion of DNA contract manufacturing; Touchlight’s synthetic dbDNA in high demand as starting material in the manufacture of advanced therapies such as mRNA vaccines and cell and gene therapies
DNA 45
45 
Touchlight completes expansion, creating one of the world’s largest DNA manufacturing facilities in London, UK
Drug Discovery Today
MAY 25, 2023
The Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines. Transformation of Grade II-listed Victorian waterworks on the River Thames in Hampton, London.
DNA 45
45 
Viral Vector Manufacturing: Current Landscape and Opportunities
Roots Analysis
FEBRUARY 27, 2024
Over the last few decades, various viral vector manufacturing have been developed, optimized and standardized for introduction of therapeutic DNA / gene of interest into a patient’s body / cells. On the other hand, among non-viral gene delivery tools, plasmid DNA has emerged as the preferred option.
Applied DNA to Participate in Upcoming Conferences
BioTech 365
MARCH 8, 2021
Applied DNA to Participate in Upcoming Conferences Applied DNA to Participate in Upcoming Conferences STONY BROOK, N.Y.–(BUSINESS –(BUSINESS WIRE)–$APDN #COVID19–Applied DNA Sciences, Inc.
DNA 40
40 
Let's personalize your content